G
o
o
g
l
e
×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
ACLARIS THERAPEUTICS DL 1 Revenue Breakdown – FWB:8AT – TradingView
www.tradingview.com
See ACLARIS THERAPEUTICS DL 1 revenue breakdown by source and country: learn where the money comes from to better understand how the company...
6 hours ago
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Yahoo Finance
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
1 week ago
Aclaris lays off 46%, resurrects zunsemetinib for cancer
Fierce Biotech
Aclaris lays off 46% of staff, resurrects zunsemetinib as potential cancer treatment ... Aclaris Therapeutics has decided to give its MK2...
3 months ago
Do Analysts Agree Monday on Aclaris Therapeutics Inc (ACRS) Stock's Target Price?
InvestorsObserver
Analysts who follow Aclaris Therapeutics Inc (ACRS) on average expect it to increase 51.26% over the next twelve months.
2 days ago
Aclaris shares plummet on terminating development of rheumatoid arthritis drug
Reuters
Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial,...
4 months ago
Aclaris Therapeutics CEO Leaves; Strategic Review Underway
MarketWatch
By Colin Kellaher Aclaris Therapeutics' top executive is leaving, as the clinical-stage biopharmaceutical company launches a strategic...
2 months ago
StockNews.com Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Hold
Defense World
StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a sell rating to a hold rating in a research report...
2 days ago
Aclaris' stocks plummet after zunsemetinib discontinuation
Clinical Trials Arena
Aclaris Therapeutics announced it is also discontinuing a Phase IIa trial of zunsemetinib in psoriatic arthritis.
4 months ago
How Will the Market React to Aclaris Therapeutics Inc (ACRS) Stock Getting a Neutral Rating
InvestorsObserver
Overall market sentiment has been neutral on Aclaris Therapeutics Inc (ACRS) stock lately. ACRS receives a Neutral rating from...
1 day ago
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Yahoo Finance
Our latest available data shows that ACRS has returned about 18.1% since the start of the calendar year. At the same time, Medical stocks have...
3 weeks ago